Development of ROS‐Sensitive Sulfasalazine‐Loaded Ferrocene Nanoparticles and Evaluation of Their Antirheumatic Effects in a 3D Synovial Hyperplasia Model
Source abstract
Abstract
Abstract Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease characterized by joint inflammation, synovial hyperplasia, and bone and cartilage destruction, which significantly impairs physical function and quality of life. Disease‐modifying antirheumatic drugs, such as sulfasalazine (SSZ), are crucial for altering the course and progression of RA; however, their clinical use is hampered by poor water solubility and lack of specificity for the reactive oxygen species (ROS)‐rich environment typical of RA. To overcome these challenges, ROS‐sensitive SSZ‐loaded ferrocene nanoparticles are developed. The nanoparticles facilitate enhanced solubility and stability of SSZ and particularly enable precision targeting through the distinctive redox properties of ferrocene. Using a 3D synovial hyperplasia model with fibroblast‐like synoviocytes derive from RA patients and validate at both the protein and gene levels, these nanoparticles significantly reduce lactate dehydrogenase, ROS, and inflammatory cytokine levels. Further validation using a collagen‐induced arthritis model demonstrates therapeutic efficacy and cytokine modulation in vivo. These findings highlight the potential of ferrocene nanoparticles as a novel and effective therapeutic strategy for RA, offering improved drug delivery and reduced systemic toxicity.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Dendrimers and Hyperbranched Polymers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Applied Bioengineering Graduate School of Convergence Science and Technology Seoul National University Seoul 08826 Republic of Korea
Center for Bio‐Healthcare Materials Bio‐Convergence Materials R&D Division Korea Institute of Ceramic Engineering and Technology Cheongju 28160 Republic of Korea
Division of Rheumatology Department of Internal Medicine Gyeongsang National University Hospital Jinju 52727 Republic of Korea
Department of Convergence Medical Science College of Medicine Gyeongsang National University Jinju 52727 Republic of Korea
Department of Chemical and Biomolecular Engineering Yonsei University 50 Yonsei‐ro, Seodaemun‐gu Seoul 03722 Republic of Korea
Department of Internal Medicine College of Medicine Gyeongsang National University Jinju 52727 Republic of Korea
THEDONEE Inc. Research Center Seoul South Korea
Funding
National Research Foundation of Korea · Korea Institute of Ceramic Engineering and Technology · Korea Health Industry Development Institute · Health Promotion Administration, Ministry of Health and Welfare · Ministerstvo Průmyslu a Obchodu · Ministry of National Defense
References (83)
Show source-provided references
1. 10.1159/00049339010.1159/000493390 ↗
2. 10.1016/j.jaut.2019.10240010.1016/j.jaut.2019.102400 ↗
3. 10.2147/OARRR.S28262710.2147/OARRR.S282627 ↗
4. Cooley H. · Arthritis Rheumatol. · 2020 · 72 · 12
5. 10.1007/s00296-023-05320-710.1007/s00296-023-05320-7 ↗
6. Lora M. · J. Rheumatol. · 2007 · 34 · 1615
7. 10.1111/j.0105-2896.2009.00859.x10.1111/j.0105-2896.2009.00859.x ↗
8. 10.3389/fimmu.2019.0139510.3389/fimmu.2019.01395 ↗
9. 10.1186/s13075-017-1303-310.1186/s13075-017-1303-3 ↗
10. Samimi L. N. · Autoimmun. Highlights · 2020 · 11 · 1110
11. 10.1046/j.1365-2567.1999.00849.x10.1046/j.1365-2567.1999.00849.x ↗
12. 10.1136/annrheumdis-2019-eular.782110.1136/annrheumdis-2019-eular.7821 ↗
13. 10.1039/C5MD00290G10.1039/C5MD00290G ↗
14. 10.1016/j.colsurfa.2018.03.04810.1016/j.colsurfa.2018.03.048 ↗
15. 10.3390/pharmaceutics1303040010.3390/pharmaceutics13030400 ↗
16. 10.1016/j.biopha.2016.03.00410.1016/j.biopha.2016.03.004 ↗
17. Sharma A. · Nano Life · 2023 · 13
18. 10.1039/C9TB02533B10.1039/C9TB02533B ↗
19. 10.1136/annrheumdis-2018-EWRR2019.12610.1136/annrheumdis-2018-EWRR2019.126 ↗
20. 10.1152/physrev.1979.59.3.52710.1152/physrev.1979.59.3.527 ↗
21. 10.1039/C6CS00196C10.1039/C6CS00196C ↗
22. 10.1021/acsami.6b1601710.1021/acsami.6b16017 ↗
23. 10.1016/j.molstruc.2021.12987410.1016/j.molstruc.2021.129874 ↗
24. 10.1002/ange.20120856810.1002/ange.201208568 ↗
25. 10.1021/acs.biomac.9b0062810.1021/acs.biomac.9b00628 ↗
26. 10.1021/acs.chemrev.8b0000610.1021/acs.chemrev.8b00006 ↗
27. 10.2147/IJN.S45895710.2147/IJN.S458957 ↗
28. 10.1016/j.autrev.2019.05.00710.1016/j.autrev.2019.05.007 ↗
29. 10.1136/annrheumdis-2015-eular.185010.1136/annrheumdis-2015-eular.1850 ↗
30. 10.1016/j.mtbio.2024.10106110.1016/j.mtbio.2024.101061 ↗
31. 10.1002/mabi.20150005710.1002/mabi.201500057 ↗
32. 10.1016/j.mtbio.2023.10077410.1016/j.mtbio.2023.100774 ↗
33. 10.1039/c3py21118e10.1039/c3py21118e ↗
34. 10.1295/polymj.23.7910.1295/polymj.23.79 ↗
35. 10.3390/ijms2311604510.3390/ijms23116045 ↗
36. 10.1039/C4RA04443F10.1039/C4RA04443F ↗
37. 10.1016/j.electacta.2023.14282410.1016/j.electacta.2023.142824 ↗
38. 10.1038/pj.2015.13310.1038/pj.2015.133 ↗
39. 10.1080/1539445X.2010.49561610.1080/1539445X.2010.495616 ↗
40. 10.1149/1945-7111/abbb4210.1149/1945-7111/abbb42 ↗
41. 10.1016/j.ijpharm.2020.11934010.1016/j.ijpharm.2020.119340 ↗
42. 10.5530/ijper.49.2.910.5530/ijper.49.2.9 ↗
43. 10.2174/221173850666618070612151510.2174/2211738506666180706121515 ↗
44. 10.3390/pr502001910.3390/pr5020019 ↗
45. 10.1039/c0py00376j10.1039/c0py00376j ↗
46. 10.1016/j.addr.2006.09.01710.1016/j.addr.2006.09.017 ↗
47. 10.1002/smll.20180157110.1002/smll.201801571 ↗
48. 10.1016/S0169-409X(02)00226-010.1016/S0169-409X(02)00226-0 ↗
49. 10.1039/C4PY01289E10.1039/C4PY01289E ↗
50. 10.1016/j.matdes.2022.11146510.1016/j.matdes.2022.111465 ↗
51. 10.1038/s41467-022-34481-510.1038/s41467-022-34481-5 ↗
52. 10.1021/nn303158910.1021/nn3031589 ↗
53. 10.1016/j.carbpol.2014.08.00310.1016/j.carbpol.2014.08.003 ↗
54. 10.1016/j.actbio.2022.04.02410.1016/j.actbio.2022.04.024 ↗
55. 10.1007/s10787-019-00608-210.1007/s10787-019-00608-2 ↗
56. 10.1007/s10856-021-06547-110.1007/s10856-021-06547-1 ↗
57. 10.3390/cells1121341010.3390/cells11213410 ↗
58. 10.1002/art.178029040310.1002/art.1780290403 ↗
59. 10.3389/fmicb.2014.0078310.3389/fmicb.2014.00783 ↗
60. 10.1097/BOR.000000000000001710.1097/BOR.0000000000000017 ↗
61. 10.3389/fimmu.2017.0134110.3389/fimmu.2017.01341 ↗
62. 10.1093/intimm/dxs04710.1093/intimm/dxs047 ↗
63. 10.3858/emm.2010.42.8.05710.3858/emm.2010.42.8.057 ↗
64. 10.1016/S0016-5085(98)84521-610.1016/S0016-5085(98)84521-6 ↗
65. 10.1016/j.joca.2006.04.00810.1016/j.joca.2006.04.008 ↗
66. 10.3390/cimb4504019710.3390/cimb45040197 ↗
67. 10.1111/j.1745-7254.2007.00500.x10.1111/j.1745-7254.2007.00500.x ↗
68. 10.3390/ijms1906180110.3390/ijms19061801 ↗
69. 10.1016/j.cytogfr.2011.10.00110.1016/j.cytogfr.2011.10.001 ↗
70. 10.1038/sj.bjp.070293710.1038/sj.bjp.0702937 ↗
71. 10.1111/j.1464-410X.2006.06321.x10.1111/j.1464-410X.2006.06321.x ↗
72. 10.1002/1529-0131(199905)42:5<963::AID-ANR15>3.0.CO;2-E10.1002/1529-0131(199905)42:5<963::AID-ANR15>3.0.CO;2-E ↗
73. 10.1006/cyto.2000.068110.1006/cyto.2000.0681 ↗
74. 10.4110/in.2022.22.e810.4110/in.2022.22.e8 ↗
75. 10.1002/art.2088510.1002/art.20885 ↗
76. Stebulis J. A. · J. Rheumatol. · 2005 · 32 · 301
77. 10.1002/cti2.114010.1002/cti2.1140 ↗
78. 10.1016/j.actbio.2016.08.05810.1016/j.actbio.2016.08.058 ↗
79. 10.1038/s12276-020-00546-y10.1038/s12276-020-00546-y ↗
80. 10.1038/nprot.2007.17310.1038/nprot.2007.173 ↗
81. 10.1136/annrheumdis-2023-eular.191310.1136/annrheumdis-2023-eular.1913 ↗
82. 10.1084/jem.2020079510.1084/jem.20200795 ↗
83. 10.1136/annrheumdis-2020-21924710.1136/annrheumdis-2020-219247 ↗